Zevra therapeutics presents new data on the long-term safety and efficacy of arimoclomol as a treatment for niemann-pick disease type c at the simd 45th annual meeting

The oral presentation highlighted data from zevra's expanded access program demonstrating a consistent safety profile

ZVRA Ratings Summary

ZVRA Quant Ranking